Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
4712 4768 4778 4819 4711 Last
1247200 1373900 1469400 1318200 3248800 Volume
-1.46% +1.19% +0.21% +0.86% -2.24% Change
Financials
Sales 2020 763 B 7 280 M 7 280 M
Net income 2020 214 B 2 046 M 2 046 M
Net cash position 2020 415 B 3 964 M 3 964 M
P/E ratio 2020 37,1x
Yield 2020 1,08%
Sales 2021 838 B 8 000 M 8 000 M
Net income 2021 249 B 2 380 M 2 380 M
Net cash position 2021 491 B 4 689 M 4 689 M
P/E ratio 2021 31,5x
Yield 2021 1,35%
Capitalization 7 921 B 75 598 M 75 586 M
EV / Sales 2020 9,84x
EV / Sales 2021 8,86x
Nbr of Employees 7 394
Free-Float 37,7%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (50.5% of net sales), bones and joints diseases treatment (34.3%), and kidney diseases (6.9%). Net sales are distributed geographically as follows: Japan (75.8%), Switzerland (20.8%) and other (3.4%). 
Sector
Pharmaceuticals
Calendar
10/22Earnings Release
More about the company
Notations Surperformance© of Chugai Pharmaceutical Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD.
09/10Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studi..
AQ
09/10Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficie..
AQ
09/10CHUGAI PHARMACEUTICAL : New Data of Chugai's Enspryng (Satralizumab) on Risk and..
BU
09/02CHUGAI PHARMACEUTICAL : Introduces LINE WORKS by WORKS MOBILE Japan for 2,400 Em..
AQ
08/27CHUGAI PHARMACEUTICAL : Launches Enspryng Subcutaneous Injection 120 mg Syringe,..
AQ
08/27CHUGAI PHARMACEUTICAL CO. LTD. : - Non-Clinical Research Results of Chugai's Swi..
AQ
08/26CHUGAI PHARMACEUTICAL : Selected as Digital Transformation Stock 2020
AQ
08/24CHUGAI PHARMACEUTICAL : Obtains Approval for Additional Indication of Kadcyla fo..
AQ
08/20ALERT : New purchases in the MarketScreener Asia portfolio
08/17CHUGAI PHARMACEUTICAL : Enspryng (Satralizumab) Receives Regulatory Approval fro..
BU
08/06Chugai Continues to be listed for All ESG Indices Selected by GPIF
AQ
07/30CHUGAI PHARMACEUTICAL : Provides an Update on Phase III COVACTA Study of Actemra..
AQ
07/30CHUGAI PHARMACEUTICAL : Roche Announces an Update on COVACTA Study for Chugai's ..
AQ
07/28CHUGAI PHARMACEUTICAL : Organizational and Personnel Changes, Chugai Proceeds St..
AQ
07/28CHUGAI PHARMACEUTICAL : Announces 2020 Half Year Results
AQ
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.
09/11CHUGAI PHARMACEUTICAL : Neue Daten von Chugais Enspryng (Satralizumab) zu Risiko..
08/20Alerte nouvelles opérations dans le portefeuille Investisseur Asie
08/17CHUGAI PHARMACEUTICAL : Enspryng (Satralizumab) von Chugai erhält FDA-Zulassung ..
07/27EN DIRECT DES MARCHES : Atos, Faurecia, Edenred, SRP Group, Solocal, SAP, Rya..
07/27Sur les marchés, la semaine pivot de l'été
More news
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4 956,42 JPY
Last Close Price 4 819,00 JPY
Spread / Highest target 45,3%
Spread / Average Target 2,85%
Spread / Lowest Target -27,4%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.43.42%75 598
JOHNSON & JOHNSON0.89%390 711
ROCHE HOLDING AG7.37%317 035
MERCK & CO., INC.-5.84%216 427
PFIZER, INC.-6.13%204 382
NOVARTIS AG-10.48%199 714